Table 2.
Mode of action | Month | At risk (n) | At risk (%) | Cumulative events (n) | Cumulative censored (n) | Strata size (n) | Drug survival propability |
---|---|---|---|---|---|---|---|
IL-17i | 0 | 190 | 100 | 5 | 0 | 190 | 100.0% |
IL-17i | 12 | 122 | 64 | 48 | 21 | 190 | 75.3% |
IL-17i | 24 | 99 | 52 | 53 | 39 | 190 | 72.6% |
JAKi | 0 | 78 | 100 | 8 | 0 | 78 | 100.0% |
JAKi | 12 | 46 | 59 | 27 | 5 | 78 | 65.4% |
JAKi | 24 | 26 | 33 | 29 | 23 | 78 | 62.8% |
TNFi | 0 | 954 | 100 | 19 | 0 | 954 | 100.0% |
TNFi | 12 | 702 | 74 | 155 | 103 | 954 | 84.4% |
TNFi | 24 | 559 | 59 | 198 | 200 | 954 | 79.6% |